Literature DB >> 19446984

Proximal aortic perforation after endovascular repair of a type B dissection in a patient with Marfan syndrome.

Jasper W van Keulen1, Frans L Moll, A Khodadade Jahrome, Joost A van Herwaarden.   

Abstract

Several successful cases of endovascular treatment of type B dissections in patients with Marfan syndrome have been reported. In our patient with Marfan syndrome, a type B dissection was successfully treated endovascularly. Three weeks after this procedure, a computed tomographic angiography (CTA) revealed a perforation of the aortic wall distal to the left subclavian artery by a bare strut of the stent graft. A second stent graft was placed to treat this complication. In patients with Marfan syndrome, complications might be prevented by using stent grafts specifically developed to treat dissections. However, specific complications, eg, perforation, must be taken into account and patients have to be followed attentively.

Entities:  

Mesh:

Year:  2009        PMID: 19446984     DOI: 10.1016/j.jvs.2009.01.045

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  3 in total

1.  Stent strut penetration during thoracic endovascular aortic repair: report of a case.

Authors:  Masao Tadakoshi; Hiroyuki Ishibashi; Tsuneo Ishiguchi; Ikuo Sugimoto; Hirohide Iwata; Tetsuya Yamada; Noriyuki Hida; Takashi Ohta
Journal:  Surg Today       Date:  2011-11-18       Impact factor: 2.549

2.  Impact of Thoracic Endovascular Repair on Pulsatile Aortic Strain in Acute Type B Aortic Dissection: Preliminary Results.

Authors:  Foeke J H Nauta; Guido H W van Bogerijen; Michele Conti; Chiara Trentin; Frans L Moll; Joost A Van Herwaarden; Ferdinando Auricchio; Santi Trimarchi
Journal:  Aorta (Stamford)       Date:  2017-04-01

3.  Contemporary management of vascular complications associated with Ehlers-Danlos syndrome.

Authors:  Benjamin S Brooke; George Arnaoutakis; Nazli B McDonnell; James H Black
Journal:  J Vasc Surg       Date:  2009-10-30       Impact factor: 4.268

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.